Lumibird (LBIRD) Q1 2025 TU earnings summary

Executive summary

• Consolidated revenue grew by 12.4% year-over-year to €49.4m in Q1 2025, with strong contributions from both Photonics and Medical divisions.

• Growth was driven by Defence/Space contracts, diagnostics, and dry eye treatment sales.

Financial highlights

• Q1 2025 revenue: €49.4m, up 12.4% from €43.9m in Q1 2024.

• Photonics division revenue rose 15.8% to €23.9m; Medical division up 9.4% to €25.5m.

• Defence/Space sales surged 37.8% to €10.5m; Industrial/Scientific up 7.0% to €5.9m.

• Medtech sales declined 2.3% to €3.9m due to delivery phasing.

• ETS sales increased 2.4% to €3.6m, reflecting a recovery after commercial reorganisation.

Outlook and guidance

• Business expansion expected to continue, supported by Defence/Space and Medical markets and increased industrial capacity.

• Minimal impact anticipated from new customs barriers, as affected products represent small volumes.